Navigation Links
Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status

Genomatix Software GmbH today announced that it has achieved GeneChip-compatibleTM status for several products with the Affymetrix Inc.

GeneChip® microarray platform and that it has joined Affymetrix GeneChip-compatible Applications Program, which provides customers with a broad spectrum of software solutions for biomedical research and development. As a GeneChip-compatible software provider, Genomatix is committed to seamlessly integrating its entire microarray analysis pipeline with the Affymetrix technology.

The Genomatix line of products which achieved GeneChip-compatibleTM status consists of ChipInspector, ChipInspector TL, ElDorado, GEMS Launcher, and BiblioSphere PathwayEdition. With those products Genomatix provides a broad set of solutions for Affymetrix GeneChip users, including analysis of data from Affymetrix whole-genome tiling and exon arrays.

"We are proud of having met the high standards of Affymetrix and earning GeneChip-compatibleTM status. The tight integration of our microarray analysis pipeline with the Affymetrix platform will stimulate exciting new results in both basic and applied biomedical R&D," said Klaus May, Director of Sales and Marketing at Genomatix. "Especially in conjunction with the new Affymetrix tiling and exon array technology, I expect that our tools will drive far greater understanding of genomic organization and transcriptome regulation."

"Affymetrix is pleased to be working with Genomatix in their efforts to develop advanced tools for analyzing GeneChip data," said Steve Lincoln, vice president of Informatics at Affymetrix. "We are particularly excited to see the emergence of next-generation commercial software which can help bring unprecedented levels of genomic resolution into the hands of applied biomedical researchers."


'"/>

Source:Genomatix Software GmbH


Page: 1

Related biology news :

1. Genomatix, AAAS ink agreement
2. Genomatix technology facilitates de novo identification of new renal disease associated genes
3. MatBase -- A new transcription factor knowledge base released by Genomatix
4. Application of Genomatix in silico methods reveals novel cancer associated genes
5. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
6. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
7. Breakthrough Microarray-based Technology for the Study of Cancer
8. Nanogen Issued Patent for Electronic Microarray With Memory
9. Characterizing Skin Cancer by Microarrays
10. Microarrays as phenotype
11. $6.5 Million Grant for Microarray Center at Yale School of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/10/2017)... Research and Markets has announced the addition of ... Commercial Aspects" to their offering. ... Biomarkers play an important ... selection of treatment as well for monitoring the results. There ... modern medicine. Biochip/microarray technologies and next generation sequencing are also ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of ... health care systems, in terms of costs and resources. However, ... the development of innovative and efficient therapies that demonstrate higher ... types of cancer treatments, a growing number of patients receiving ...
(Date:3/22/2017)... -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major ... and GSK to generate genetic sequence data from the 500,000 ... enable researchers to gain valuable insights to support advances in ... serious and life threatening diseases. ... Genetic evidence has revolutionized scientific ...
(Date:3/22/2017)... JERUSALEM , March 22, 2017 ... ( www.oramed.com ), ... of oral drug delivery systems, announced today that ... Officer, will deliver a presentation titled, "Oral Insulin ... upcoming Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics ...
Breaking Biology Technology: